Biotech - Gene Therapy
•91 stocks
•
Total Market Cap: Loading...
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (91)
| Company | Market Cap | Price |
|---|---|---|
|
LLY
Eli Lilly and Company
Gene therapy / gene editing modalities are being pursued in Lilly's pipeline and collaborations.
|
$816.66B |
$863.11
+2.20%
|
|
GILD
Gilead Sciences, Inc.
CAR-T therapies involve genetic modification, aligning with Biotech - Gene Therapy.
|
$149.01B |
$119.77
+1.12%
|
|
VRTX
Vertex Pharmaceuticals Incorporated
CASGEVY is a gene-edited, one-time therapy, aligning with gene therapy as a major, investable modality.
|
$109.29B |
$425.63
+1.37%
|
|
REGN
Regeneron Pharmaceuticals, Inc.
Gene therapy programs (e.g., DB-OTO) place Regeneron in the gene therapy space.
|
$69.08B |
$651.52
-0.39%
|
|
INSM
Insmed Incorporated
INS1201 intrathecally delivered gene therapy for Duchenne muscular dystrophy places Insmed in the Gene Therapy biotech space.
|
$40.08B |
$189.55
-2.40%
|
|
NBIX
Neurocrine Biosciences, Inc.
Neurocrine is pursuing gene therapy programs in collaboration with Voyager Therapeutics, representing a gene therapy Biotech modality.
|
$14.20B |
$143.19
+3.73%
|
|
BBIO
BridgeBio Pharma, Inc.
BBP-812 is an AAV9 gene therapy candidate for Canavan disease, a gene therapy product.
|
$11.97B |
$62.65
-1.14%
|
|
KRYS
Krystal Biotech, Inc.
Krystal Biotech's core HSV-1 gene therapy platform and lead product VYJUVEK directly represent a gene therapy business.
|
$5.71B |
$196.63
+3.99%
|
|
CRSP
CRISPR Therapeutics AG
CRISPR-based ex vivo gene-editing therapy CASGEVY is a gene therapy product.
|
$5.53B |
$64.02
+4.78%
|
|
PTCT
PTC Therapeutics, Inc.
Upstaza/Kebilidi gene therapy represents a direct gene therapy product approved and marketed.
|
$5.41B |
$68.28
+0.25%
|
|
QURE
uniQure N.V.
Core business is development and commercialization of gene therapies (e.g., AMT-130) using viral vectors, i.e., direct gene therapy products.
|
$3.71B |
$67.67
-0.28%
|
|
CGON
CG Oncology, Inc. Common stock
Cretostimogene grenadenorepvec is a gene therapy vector (oncolytic immunotherapy) targeting bladder cancer, aligning with gene therapy players.
|
$3.30B |
$43.28
+1.91%
|
|
RARE
Ultragenyx Pharmaceutical Inc.
Company's portfolio includes multiple gene therapy programs using AAV vectors (DTX401, UX111, UX701), aligning with Biotech - Gene Therapy.
|
$3.27B |
$34.58
-1.68%
|
|
KNSA
Kiniksa Pharmaceuticals, Ltd.
KPL-1161 is an Fc-modified IL-1R1 antibody in preclinical development, supporting the broader immunology/antibody therapeutics pipeline.
|
$2.74B |
$36.98
-0.83%
|
|
BEAM
Beam Therapeutics Inc.
Beam's core offering is a base editing gene therapy platform (DNA editing to correct disease-causing mutations).
|
$2.51B |
$25.01
+5.08%
|
|
SRPT
Sarepta Therapeutics, Inc.
Directly develops gene therapies (ELEVIDYS) and other gene therapy programs; gene therapy is Sarepta's core biotech focus.
|
$2.36B |
$24.00
+3.23%
|
|
GLPG
Galapagos N.V.
CAR-T/gene-modified cell therapies fall under gene therapy concepts.
|
$2.09B |
$31.78
+1.40%
|
|
STOK
Stoke Therapeutics, Inc.
The company’s approach falls under gene therapy/genetic medicines, a recognized investable biotech theme.
|
$1.64B |
$30.01
-5.33%
|
|
NTLA
Intellia Therapeutics, Inc.
Direct focus on CRISPR-based in vivo gene therapies (NTLA-2002 and nex-z) and a delivery platform, i.e., core gene-therapy biotech business.
|
$1.31B |
$12.62
+2.85%
|
|
PGEN
Precigen, Inc.
Direct platform and lead asset are gene therapy products, making Biotech - Gene Therapy a core tag.
|
$1.22B |
$4.14
+2.35%
|
|
SANA
Sana Biotechnology, Inc.
The company uses gene-editing technologies to modify cells (e.g., via CRISPR-related Beam collaboration) for therapeutic cell therapies.
|
$1.12B |
$4.94
+0.82%
|
|
TSHA
Taysha Gene Therapies, Inc.
TSHA-102 is an AAV9-based gene therapy product directly developed by Taysha for Rett syndrome.
|
$1.06B |
$4.96
+1.02%
|
|
IMTX
Immatics N.V.
Genetic modification of patient cells aligns with gene therapy concepts (TCR engineering).
|
$1.05B |
$10.19
-2.21%
|
|
PCRX
Pacira BioSciences, Inc.
Acquisition of GQ Bio Therapeutics adds an HCAd gene therapy platform and preclinical assets.
|
$989.99M |
$21.42
+0.71%
|
|
VERV
Verve Therapeutics, Inc.
Verve Therapeutics' core offering is in vivo gene therapy using base editing delivered to liver cells, aligning with Biotech - Gene Therapy.
|
$988.30M |
$11.13
|
|
MRVI
Maravai LifeSciences Holdings, Inc.
MRVI supplies inputs and platforms that support gene therapy & RNA-based therapeutics, aligning with Biotech - Gene Therapy.
|
$799.63M |
$3.13
-0.16%
|
|
REPL
Replimune Group, Inc.
Engineered viral vectors delivering therapeutic payloads resemble gene therapy approaches.
|
$750.05M |
$9.73
-5.07%
|
|
MGTX
MeiraGTx Holdings plc
Core business involves developing gene therapies using AAV vectors and a riboswitch platform; MeiraGTx is a clinical-stage biotechnology company focused on genetic medicines.
|
$729.72M |
$9.07
+3.89%
|
|
PRME
Prime Medicine, Inc.
Directly develops gene editing therapeutics (Prime Editing) and the core therapeutic platform, i.e., gene therapy.
|
$648.59M |
$4.95
+13.68%
|
|
RGNX
REGENXBIO Inc.
Core product category: gene therapy using NAV AAV platform.
|
$640.55M |
$12.76
-0.47%
|
|
FDMT
4D Molecular Therapeutics, Inc.
FDMT is a gene therapy-focused biotech company developing therapeutic candidates using its proprietary vector platform (lead programs 4D-150 and 4D-710).
|
$532.73M |
$11.52
+1.77%
|
|
NGNE
Neurogene Inc.
NGNE directly develops gene therapy candidates (NGN-401) and uses a gene therapy platform, matching Biotech - Gene Therapy.
|
$488.62M |
$34.26
+3.36%
|
|
OCGN
Ocugen, Inc.
Ocugen's modifier gene therapy platform and lead retinal candidates (OCU400/OCU410) are gene therapy products targeting vision disorders.
|
$455.57M |
$1.55
+4.73%
|
|
BNTC
Benitec Biopharma Inc.
BB-301 is an AAV-based gene therapy leveraging gene silencing and wildtype replacement, aligning with Gene Therapy.
|
$418.82M |
$16.37
+1.24%
|
|
SLDB
Solid Biosciences Inc.
Solid Biosciences is developing viral-vector gene therapies (SGT-3.00, SGT-212, SGT-501) and related products, fitting squarely under Biotech - Gene Therapy.
|
$417.81M |
$5.38
+1.41%
|
|
AUTL
Autolus Therapeutics plc
CAR-T therapies involve genetic modification; aligns with gene therapy category.
|
$412.52M |
$1.55
+2.98%
|
|
RCKT
Rocket Pharmaceuticals, Inc.
Direct gene therapy platform encompassing ex vivo LV and in vivo AAV modalities.
|
$406.17M |
$3.77
+1.89%
|
|
KRRO
Korro Bio, Inc.
Platform-level gene therapy modality via RNA editing aligns with gene therapy-focused Biotech tag.
|
$384.17M |
$41.05
+12.61%
|
|
ENGN
enGene Holdings Inc.
engGene's core platform is non-viral gene therapy delivery (DDX platform) and its lead asset is a gene therapy product, placing it squarely in Gene Therapy.
|
$368.47M |
$7.20
+3.38%
|
|
SLN
Silence Therapeutics plc
RNAi therapies are a gene-silencing modality, aligning with gene therapy-related biotechnology themes.
|
$337.72M |
$7.10
-2.87%
|
|
LXEO
Lexeo Therapeutics, Inc. Common Stock
Company is focused on AAV-based gene therapies (LX2006, LX2020) delivering therapeutic genes — direct Gene Therapy business.
|
$332.30M |
$10.01
+6.15%
|
|
GNLX
Genelux Corporation
Olvi-Vec uses a modified vaccinia virus as a viral-vector therapy, classifiable under Gene Therapy.
|
$304.90M |
$8.07
+1.38%
|
|
KYTX
Kyverna Therapeutics, Inc.
CAR-T approaches involve genetically modifying cells, situating KYTX within the Gene Therapy category.
|
$301.24M |
$6.96
+3.19%
|
|
ALLO
Allogene Therapeutics, Inc.
Involves gene editing in its cell therapy platform (TALEN-based) making it align with gene therapy category.
|
$271.23M |
$1.24
+2.07%
|
|
ARCT
Arcturus Therapeutics Holdings Inc.
mRNA-based therapies are gene-expression modalities and align with gene therapy as an advanced nucleic-acid therapeutic approach.
|
$270.39M |
$9.98
+3.69%
|
|
CADL
Candel Therapeutics, Inc.
CAN-2409 and CAN-3110 are viral vector-based therapies, aligning with gene therapy.
|
$269.55M |
$5.38
-3.67%
|
|
VYGR
Voyager Therapeutics, Inc.
Voyager’s core offerings are gene therapies and gene-delivery platforms, including APOE and tau-targeted approaches.
|
$258.42M |
$4.67
+3.32%
|
|
EDIT
Editas Medicine, Inc.
Core product category: in vivo gene therapy using Editas's gene-editing platform (AsCas12a) delivered via targeted lipid nanoparticles (tLNP).
|
$257.84M |
$3.07
+1.99%
|
|
INZY
Inozyme Pharma, Inc.
The company is conducting preclinical and clinical work on a gene therapy construct for ENPP1, indicating engagement in gene therapy modalities.
|
$256.96M |
$4.00
|
|
CLLS
Cellectis S.A.
TALEN gene-editing platform underpins its gene-editing and gene therapy approaches for T-cells.
|
$248.72M |
$3.46
-0.57%
|
|
ABEO
Abeona Therapeutics Inc.
ZEVASKYN is a gene therapy using autologous cells, placing Abeona in the gene therapy space.
|
$246.06M |
$4.80
-5.41%
|
|
LYEL
Lyell Immunopharma, Inc.
Engineering of T cells and consideration of gene-editing aspects positions Lyell in Gene Therapy.
|
$246.02M |
$16.59
+0.36%
|
|
TNYA
Tenaya Therapeutics, Inc.
Tenaya's lead programs TN-201 and TN-401 are gene therapies (AAV-based) targeting genetic heart diseases.
|
$234.24M |
$1.46
+15.87%
|
|
PRQR
ProQR Therapeutics N.V.
The company employs gene therapy modalities via RNA editing to treat genetic diseases.
|
$231.68M |
$2.75
+0.92%
|
|
CRBU
Caribou Biosciences, Inc.
Company is developing gene-editing gene therapy platforms (CRISPR-based chRDNA) for therapeutic applications.
|
$225.07M |
$2.42
+4.53%
|
|
RNAC
Cartesian Therapeutics, Inc.
CAR-T cell modification involves genetic alteration of cells, aligning with gene therapy categories.
|
$212.05M |
$8.15
+0.55%
|
|
CRGX
CARGO Therapeutics, Inc. Common Stock
CAR-T/modification of cells implicates gene therapy approaches within Biotech - Gene Therapy.
|
$206.13M |
$4.47
|
|
CABA
Cabaletta Bio, Inc.
Gene therapy approach underpinning the CAR-T cell modification used in rese-cel.
|
$183.18M |
$3.60
+45.95%
|
|
MXCT
MaxCyte, Inc.
Expansion into gene editing assessment services via SeQure Dx associates MaxCyte with gene therapy modalities.
|
$163.73M |
$1.53
+1.66%
|
|
VOR
Vor Biopharma Inc.
Platform involves genome editing of hematopoietic stem cells to enable therapeutic strategies, a gene therapy approach.
|
$150.64M |
$24.23
-3.06%
|
|
SGMO
Sangamo Therapeutics, Inc.
Core platform enabling genomic medicine via gene therapy and genome regulation (ZF/ZFR) technology.
|
$139.43M |
$0.59
+3.99%
|
|
IRD
Opus Genetics, Inc.
Core product area: AAV-based gene therapies for inherited retinal diseases (OPGx-LCA5, OPGx-BEST1).
|
$137.22M |
$2.28
+15.74%
|
|
MGX
Metagenomi, Inc. Common Stock
MGX's core platform is gene therapy/gene editing tools enabling therapeutic gene modification, including in vivo MGX-1.00 programs.
|
$94.95M |
$2.52
+3.28%
|
|
DTIL
Precision BioSciences, Inc.
ARCUS is Precision BioSciences' in vivo gene editing platform and the lead programs PBGENE-HBV and PBGENE-DMD are built on this technology for therapeutic gene edits.
|
$90.48M |
$8.07
-6.27%
|
|
ADVM
Adverum Biotechnologies, Inc.
Lead program Ixo-vec is a gene therapy for an ocular indication, placing Adverum in the Biotech - Gene Therapy category.
|
$89.83M |
$4.30
+1.65%
|
|
INO
Inovio Pharmaceuticals, Inc.
INO's core DNA medicines platform and lead candidate INO-3107 are gene therapy products based on DNA plasmids delivered via CELLECTRA; maps to gene therapy.
|
$86.18M |
$2.35
-0.64%
|
|
CAMP
CAMP4 Therapeutics Corporation
Platform focuses on gene modulation/gene therapy-type approaches via regRNA and RNA-based therapeutics.
|
$83.87M |
$4.13
+2.61%
|
|
FBIO
Fortress Biotech, Inc.
MBIO’s gene therapy initiatives place Fortress under Biotech - Gene Therapy.
|
$75.70M |
$2.56
-0.19%
|
|
EUDA
EUDA Health Holdings Limited
Planned gene editing/gene therapy capabilities align with advanced Biotech initiatives.
|
$75.06M |
$2.06
+0.49%
|
|
ACET
Adicet Bio, Inc.
Engages in gene-editing/advanced gene therapy approaches as part of its next-generation cell therapy programs (ADI-212).
|
$62.03M |
$0.75
-3.81%
|
|
GUTS
Fractyl Health, Inc. Common Stock
Rejuva gene therapy platform (RJVA-001) and related candidates (RJVA-002) classify as Biotech - Gene Therapy, a core product line aimed at durable disease modification.
|
$60.24M |
$1.24
+0.41%
|
|
COEP
Coeptis Therapeutics, Inc.
Biotech - Gene Therapy aligns with SNAP-CAR and related gene-editing platforms.
|
$53.48M |
$14.76
-3.47%
|
|
BRNS
Barinthus Biotherapeutics plc
Viral vector platform (ChAdOx and MVA) for immunotherapy indicates gene therapy modalities.
|
$53.13M |
$1.30
+1.16%
|
|
SNTI
Senti Biosciences, Inc.
Engages in gene therapy/gene circuit technology underlying SENTI-202 platform (synthetic biology in therapeutics).
|
$52.94M |
$2.04
-3.77%
|
|
IPSC
Century Therapeutics, Inc.
Goes beyond traditional cell therapies with gene-editing (CRISPR) to create and modify therapeutic cells.
|
$50.24M |
$0.58
-1.25%
|
|
GNTA
Genenta Science S.p.A.
Genenta's lead program is a gene therapy platform.
|
$47.00M |
$2.62
-8.71%
|
|
JANL
Janel Corporation
Adenovirus production services indicate viral-vector manufacturing for gene therapy applications (Life Sciences CM/CMO activity).
|
$37.96M |
$32.00
|
|
GDTC
CytoMed Therapeutics Limited
Gene therapy-related platform and engineered cell therapies (CAR-like strategies) fit Biotech - Gene Therapy.
|
$25.39M |
$2.28
+6.05%
|
|
PASG
Passage Bio, Inc.
PBFT02 is Passage Bio's lead gene therapy program directly developed by the company.
|
$23.86M |
$7.63
+3.18%
|
|
SYBX
Synlogic, Inc.
The platform uses engineered microbes to deliver therapeutic payloads, aligning with biotech gene therapy‑like applications.
|
$19.77M |
$1.68
-1.75%
|
|
PHGE
BiomX Inc.
BiomX develops phage-based therapeutic modalities and personalized bacterial therapies, aligning with biotech gene therapy category.
|
$12.93M |
$0.51
-5.91%
|
|
HIGR
Hi-Great Group Holding Company
KRAS-related licensing potentially ties to gene therapy platforms or gene-targeted therapeutics.
|
$12.30M |
$0.12
|
|
GOVX
GeoVax Labs, Inc.
Gedeptin is an oncolytic gene-directed therapy leveraging GeoVax's platform, qualifying as gene therapy biotech product.
|
$8.60M |
$0.55
-1.65%
|
|
BLRX
BioLineRx Ltd.
Motixafortide's use in gene therapy mobilization aligns the company with gene therapy-focused themes.
|
$8.32M |
$3.48
+0.87%
|
|
TSBX
Turnstone Biologics Corp.
Company referenced an oncolytic viral platform, a viral-based therapeutic modality with potential gene-therapy overlap.
|
$8.21M |
$0.35
|
|
MBIO
Mustang Bio, Inc.
Oncolytic virus therapy and viral/gene-therapy approaches position MBIO in gene therapy category.
|
$6.35M |
$1.44
-1.71%
|
|
IMNN
Imunon, Inc.
IMNN-001 uses a DNA-based delivery approach consistent with Gene Therapy.
|
$4.43M |
$4.54
+1.22%
|
|
CLDI
Calidi Biotherapeutics, Inc.
Calidi employs viral vectors for therapeutic payload delivery (gene therapy approach) in its RedTail/IL-15 payload strategy.
|
$4.08M |
$1.52
-3.48%
|
|
CARM
Carisma Therapeutics, Inc.
In vivo CAR-M therapies via mRNA-LNP point to gene-delivery/gene-therapy modality components in the asset pipeline.
|
$2.36M |
$0.15
+160.68%
|
|
ELAB
PMGC Holdings Inc.
Northstrive’s engineered probiotic therapeutics framework aligns with gene-therapy–adjacent biopharmaceutical platforms.
|
$2.33M |
$5.87
-2.74%
|
|
CERO
CERo Therapeutics Holdings, Inc.
CER-T involves genetic modification of T cells, placing it in the Gene Therapy category.
|
$27220 |
$0.10
+1.58%
|
Loading company comparison...
Loading industry trends...
Loading research report...
